AAArgyrides Argyrou

Argyrides Argyrou

*This is an algorithmically generated author record based on publicly available information.

Argyrides Argyrou has a total of 378 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanistic characterization of heterobifunctional modalities using biochemical methods

    by Ryan Guilbert, George Hughes, Maxime Couturier, Syedah Neha Ashraf, Argyrides Argyrou

  • Correction to “Targeting the Interaction of NRF2 and β-TrCP with Molecular Glues”

    by Daniel H. O Donovan, Jon Winter-Holt, Gavin W. Collie, Maria E. Cuomo, David John McGarry, Millie Fox, Bo Kyung Alex Seong, Ursula Grazini, Peter Barton, David Longmire, et al.

  • Targeting the Interaction of NRF2 and β-TrCP with Molecular Glues

    by Daniel H. O Donovan, Jon Winter-Holt, Gavin W. Collie, Maria Emanuela Cuomo, David John McGarry, Millie Fox, Bo Kyung Alex Seong, Ursula Grazini, Peter Barton, David Longmire, et al.

    Inhibiting the oncogenic driver NRF2 in non-small cell lung cancer (NSCLC) represents a promising yet challenging clinical opportunity. Small molecules that enhance the NRF2:β-TrCP interaction (“molecular glues”) could hold therapeutic potential by promoting the ubiquitination and proteasomal degradation of NRF2. NRX-252114 is a molecular glue previously reported to promote the interaction between β-catenin and β-TrCP. We now find that NRX-252114 can also enhance the association between β-TrCP and NRF2 phosphodegron peptides. To leverage this novel interaction for the development of NRF2:β-TrCP molecular glues, we synthesized and evaluated a library of chemical analogues, guided by homology modeling and subsequently by X-ray crystallography. Surprisingly, structural elucidation of the NRF2:β-TrCP complex revealed occlusion of the presumed molecular glue binding pocket. This mechanistic insight explains the limited affinity enhancement for analogues of NRX-252114, and provides a structural rationale for the lack of NRF2 degradation in cells. Our findings broaden the scope of β-TrCP-targeted molecular glues, demonstrate that NRF2 is “glueable” at the peptide level, and provide mechanistic guidance for future efforts to target the pharmacologically elusive NRF2 pathway in cancer.


  • Open Access

    Structural Studies of βTrCP Reveal Plasticity in Binding Modes of Consensus and Nonconsensus Degrons

    by Gavin W. Collie, Hazel Mak, Marta Acebrón-García-De-Eulate, Argyrides Argyrou, Maxime Couturier, Maria Emanuela Cuomo, Daniel H. O Donovan, Isabella C. Russell, Geoffrey Wells, Jon Winter-Holt

    The E3 ligase βTrCP regulates a significant number of important cytosolic proteins by recognizing and binding to a “DSGXXS” consensus phosphodegron sequence, resulting in the ubiquitination and degradation of target proteins. While many of the substrates of βTrCP have strong disease links, there is high-resolution structural data available for just one of these proteins in complex with βTrCP. Here, we describe the development of a robust crystallographic system for βTrCP and report high-resolution crystal structures for βTrCP in complex with degrons from five new targets, encompassing the important cancer proteins, WEE1, claspin, ATF4, PDCD4, and IκBα. Interestingly, these structures reveal the molecular basis by which βTrCP can recognize and bind both consensus and nonconsensus degron peptides and reveal an overall general plasticity in degron binding mode. We also provide a biochemical assessment of the binding affinities of these peptides for βTrCP, adding further insight into the molecular interactions observed in the crystal structures. Finally, computational analyses of the βTrCP complexes identify opportunities for potential molecular glue approaches.

  • Top Cited Papers

    Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer

    by James S. Scott, Laura Evans, Peter C. Astles, Argyrides Argyrou, Sharan K. Bagal, David Beattie, Erin L. Braybrooke, Doyle J. Cassar, Claire Crafter, Coura Diène, et al.

    Androgen Receptor (AR) signaling plays a pivotal role in the development and progression of prostate cancer. Herein, we describe the discovery and optimization of a novel series of AR PROTACs capable of degrading AR and important resistance mutations such as L702H AR. A novel AR-binding cyanoindole motif was identified from a directed screen of the AstraZeneca collection. This was optimized and elaborated to identify a suitable exit vector from which to form an initial PROTAC capable of degrading AR. The series was further optimized in terms of potency and rodent oral bioavailability with an isomeric switch of the piperidine substitution, removing an in vitro mitotoxicity signal to give 3n. This compound inhibited AR signaling in vitro and was able to inhibit tumor growth in vivo in a mouse prostate cancer xenograft model. Extensive profiling in terms of drug-like properties allowed this to be progressed into development as AZD9750.


  • Discovery and Characterization of Diverse Non-nucleotide Inhibitors of DNPH1 Using an Integrated Hit Finding Strategy

    by Benjamin C. Whitehurst, Niall A. Anderson, Argyrides Argyrou, Peter Astles, Bernard Barlaam, Elaine B. Cadogan, Luca Carlino, Gavin W. Collie, Alex Edwards, Linda Kitching, et al.

    DNPH1 is a hydrolase enzyme that degrades the noncanonical nucleotide 5-hydroxymethyl-2'-deoxyuridine 5'-monophosphate (hmdUMP), thus acting as a nucleotide pool sanitizer by preventing its aberrant incorporation into DNA. Recent studies have shown that loss of DNPH1 enhances the sensitivity of homologous recombination repair-deficient cancer cells to PARP inhibitors, highlighting its potential as an attractive therapeutic target. Herein we report the design and prosecution of an integrated hit finding strategy combining high-throughput screening, DNA-encoded library screening, and fragment-based lead generation which enabled the discovery of the first non-nucleotide ligands for DNPH1. We compare four hit compounds which differ markedly in their chemical structures, physicochemical properties, and binding modes and summarize parallel hit-to-lead workup efforts. We also provide discussion of the merits of an integrated approach for hit discovery when applied to challenging novel targets such as DNPH1.


  • Discovery and Optimization of a Non-Nucleoside-Based Series of Inhibitors of 2′-Deoxynucleoside 5′-Monophosphate Glycosidase (DNPH1)

    by Bernard Barlaam, Luz Alonso-Crisostomo, Niall A. Anderson, Argyrides Argyrou, Peter C. Astles, Elaine B. Cadogan, Luca Carlino, Gavin W. Collie, Nichola L. Davies, James Hall, et al.

    DNPH1 is a nucleotide pool sanitizer that cleaves 5-hydroxymethyl-2-deoxyuridine-5-monophosphate (hmdUMP), preventing incorporation of the correspondent non-natural nucleotide into DNA. Recent findings have demonstrated that loss of DNPH1 could potentiate the sensitivity of PARP inhibitors in homologous recombination repair (HRR)-deficient cancers. We report the optimization of a non-nucleoside-based series of DNPH1 inhibitors. Starting from a weak compound 1 (binding affinity pIC50 4.7), we identified compound 38 as a very potent inhibitor of DNPH1 (pIC50 9.3) using DNPH1 X-ray structure-guided drug design. Compound 38 demonstrated target engagement of DNPH1 in the SUM149PT cell line (pIC50 7.2). Using this tool compound, we then report the in vitro pharmacology of a DNPH1 inhibitor in the BRCA1 mutant SUM149PT cell line.


  • Use of Direct-to-Biology Strategies for the Discovery of 2′-Deoxynucleoside 5′-Monophosphate N-Glycosidase (DNPH1) PROTACs

    by Niall A. Anderson, Bernard Barlaam, Argyrides Argyrou, Peter C. Astles, Hanna Bruss, Elaine B. Cadogan, Luca Carlino, Luz Alonso-Crisostomo, Gavin W. Collie, Alex J. Edwards, et al.

    2'-Deoxynucleoside 5'-monophosphate N-glycosidase (DNPH1) has emerged as an attractive target for cancer therapeutics exploiting DNA damage response pathways, yet chemical degraders for interrogating DNPH1 biology are lacking. We report the accelerated discovery of potent DNPH1 PROTACs using a direct-to-biology synthesis and screening platform. We employed miniaturized, array-based chemistry to generate a broad library of quinazoline-based PROTACs capable of recruiting a variety of different E3 ligases. Screening crude reaction mixtures in a cellular degradation assay enabled rapid identification of multiple nanomolar DNPH1 PROTACs, exemplified by compound 59, which achieved near-complete DNPH1 degradation and demonstrated strong functional activity in BRCA1 mutant cell lines. Mechanistic studies confirmed selective, proteasome- and VHL-dependent protein knockdown and recapitulation of phenotypic outcomes observed with DNPH1 genetic loss, including sensitization to hmdU treatment. Our findings highlight the power of D2B methodology to streamline PROTAC development and establish quinazoline-based degraders as robust chemical tools to advance DNPH1-targeted cancer research.


  • Open Access

    A Complete Mechanistic Framework for Molecular Glue Characterization

    by Maxime Couturier, Ryan Guilbert, Paul Clarkson, Argyrides Argyrou

    The use of molecular glues to modulate protein-protein interactions has emerged as a promising approach to drug previously intractable targets. Despite strong interest in this modality, a comprehensive theoretical framework is lacking. We have established a complete mechanistic analysis which enables the determination of molecular glues' binding and cooperativity values from a simple biochemical matrix experiment. We validated the model using numerical integration and experimental data from fluorescence resonance energy transfer and fluorescence polarization assays. As the derived models enable the determination of all thermodynamic parameters of any molecular glue, they have significant applications in drug discovery, particularly for molecular glue optimization and characterization of neo-substrates.


  • Open Access

    A high-throughput compatible workflow for the biochemical identification and characterization of molecular glues

    by Ryan Guilbert, Maxime Couturier, Yuanyuan Si, Daniel O’ Donovan, David Longmire, Hazel Mak, Paul Clarkson, Argyrides Argyrou